The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Month: October 2018

MaaT Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of Lead Product MaaT013, a First-in-Class Biotherapeutic to Treat Acute GvHD
Clinical & Manufacturing

MaaT Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of Lead Product MaaT013, a First-in-Class Biotherapeutic to Treat Acute GvHD

OCT 15, 2018
Synthetic Biologics Prices $18,000,000 Public Offering
Finance

Synthetic Biologics Prices $18,000,000 Public Offering

OCT 12, 2018
Researchers Link Gut Bacteria to Heart Transplant Success or Failure
Pharma & Human Health

Researchers Link Gut Bacteria to Heart Transplant Success or Failure

OCT 11, 2018
Valbiotis Appoints Murielle Cazaubiel as Head of Development and Medical Affairs
Pharma & Human Health

Valbiotis Appoints Murielle Cazaubiel as Head of Development and Medical Affairs

OCT 10, 2018
DNAnexus-Powered Mosaic Microbiome Platform Announces Winners of Second Community Challenge
Pharma & Human Health

DNAnexus-Powered Mosaic Microbiome Platform Announces Winners of Second Community Challenge

OCT 5, 2018
Gram-negative Bacteria Increase Mortality, Vasopressor use and ICU Admission in ILD Patients
Pharma & Human Health

Gram-negative Bacteria Increase Mortality, Vasopressor use and ICU Admission in ILD Patients

OCT 5, 2018
Vedanta Biosciences Announces Successful Phase 1a/1b Data for Lead, Rationally Defined Bacterial Consortium Product Candidate
Infectious Disease & AMR

Vedanta Biosciences Announces Successful Phase 1a/1b Data for Lead, Rationally Defined Bacterial Consortium Product Candidate

OCT 4, 2018
Reading Between the Lines: What the FDA Public Workshop Really Tells Us About the Regulation of Microbiome-Based Products
Editor's Choice

Reading Between the Lines: What the FDA Public Workshop Really Tells Us About the Regulation of Microbiome-Based Products

OCT 3, 2018
Synlogic Appoints Dr. Aoife Brennan as President and Chief Executive Officer
Biotics and Supplements

Synlogic Appoints Dr. Aoife Brennan as President and Chief Executive Officer

OCT 2, 2018
Pivot Bio Closes $70 Million Series B Financing to Deliver First and Only Clean Alternative to Synthetic Nitrogen Fertilizer
Finance

Pivot Bio Closes $70 Million Series B Financing to Deliver First and Only Clean Alternative to Synthetic Nitrogen Fertilizer

OCT 2, 2018
Innovation Industries joins €18m Series A financing round of A-MANSIA
Finance

Innovation Industries joins €18m Series A financing round of A-MANSIA

OCT 1, 2018